Crossmark

Baricitinib Safety for Events of Special Interest in Populations at Risk: Analysis from Randomised Trial Data Across Rheumatologic and Dermatologic Indications

Crossref DOI link: https://doi.org/10.1007/s12325-023-02445-w

Published Online: 2023-02-20

Published Print: 2023-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Taylor, Peter C. https://orcid.org/0000-0001-7766-6167
Bieber, Thomas

Alten, Rieke

Witte, Torsten

Galloway, James

Deberdt, Walter

Issa, Maher

Haladyj, Ewa

De La Torre, Inmaculada

Grond, Susanne

Wollenberg, Andreas
Funding

Funding for this research was provided by:

Eli Lilly and Company
License Information

Text and Data Mining valid from 2023-02-20

Version of Record valid from 2023-02-20
More Information

Article History

Received: 5 December 2022

Accepted: 25 January 2023

First Online: 20 February 2023

Change Date: 11 July 2025

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1007/s12325-025-03244-1

Updates are available Correction dated 2025-07-11

Click to view Correction: https://doi.org/10.1007/s12325-025-03244-1